APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase II drugs for Non-Proliferative Diabetic Retinopathy (NPDR) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APX-3330’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APX-3330 overview
APX-3330 is under development for the treatment of solid tumors including pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, endometrial cancer, melanoma, prostate cancer and colorectal cancer, diabetic macular edema, non proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), hematological cancers including acute lymphoblastic leukemia, malignant peripheral nerve sheath tumor (MPNST), laser-induced choroidal neovascularization, inflammation, inflammatory bowel disease, gall bladder cancer, hepatocellular cancer, bladder cancer and ovarian cancer. It is a new chemical entity and is administered orally as a tablet. The drug candidate acts by targeting Ref-1 and TNF synthesis.
It was also under development for the treatment of hepatic failure, chronic hepatitis C and chemotherapy-induced peripheral neuropathy, tuberous sclerosis complex (TSC), wet age-related macular degeneration.
Opus Genetics overview
Opus Genetics is a clinical-stage biopharmaceutical company that develops novel therapies for retinal and refractive eye disorders. The company’s product candidates include APX3330, a small-molecule inhibitor of Ref-1, and Phentolamine Ophthalmic Solution 0.75% (PS), an eye drop formulation of phentolamine mesylate. Its APX3330 is being developed for the treatment of diabetic retinopathy and diabetic macular edema. The company markets its products under the brand RYZUMVI. Opus Genetics‘ products are aimed at addressing the unmet needs of patients with various eye disorders, including those suffering from diabetic retinopathy, a condition that affects millions of diabetics worldwide. The company collaborates with Viatris, Inc. for the development and commercialization of its refractive product candidate. Opus Genetics is headquartered in Farmington Hills, Michigan, the US.
For a complete picture of APX-3330’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
